Systemic Lupus Erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease. In this disease, the body’s immune system mistakenly attacks its own healthy cells and tissues instead of protecting them from harmful pathogens, like bacteria and viruses.
The word “systemic” refers to the disease that can affect multiple organs throughout the body, whereas “erythematosus” means the characteristic red skin rash that some patients develop. SLE can range from mild to severe and often progresses through periods of flare-ups (when symptoms worsen) and remission (when symptoms improve or disappear).
While the exact cause of SLE is unknown, it can be due to a combination of several factors, including:
- Genetics
- Hormonal changes
- Environmental factors
- Immune system dysfunction
Common symptoms of SLE can vary with the patient. It includes:
- Persistent fatigue
- Joint pain and swelling
- Butterfly-shaped rash across the cheeks and nose
- Fever
- Hair loss
- Photosensitivity
- Mouth or nasal ulcers
- Chest pain
- Swollen lymph nodes
- Kidney problems
- Raynaud’s phenomenon (fingers turning white or blue in cold temperatures)
During SLE, immune cells, especially B lymphocytes, produce autoantibodies. As a result, the immune system mistakenly recognizes the body’s own proteins, DNA, and cellular components as foreign.
These antibodies combine with self-antigens to form immune complexes that accumulate in tissues and trigger inflammation and organ damage.
Since SLE has no cure, it can be controlled if diagnosed early. So, early diagnosis and treatment for SLE are crucial. Here is where the anti-ARID3A antibody comes into play.
Table of Contents
What is an Anti-ARID3A Antibody?
An anti-ARID3A antibody is specifically designed to bind the ARID3A protein. These antibodies allow scientists to visualize and measure the amount of ARID3A protein in biological samples.
These antibodies are widely used in:
- Western blotting (WB)
- Immunohistochemistry (IHC)
- Immunofluorescence (IF)
- Flow cytometry (FC)
- Immunoprecipitation (IP)
- Chromatin immunoprecipitation (ChIP)
- Enzyme-linked immunosorbent assay (ELISA)
ARID3A belongs to the ARID family of DNA-binding transcription factors. It regulates the expression of genes involved in immune cell development, especially within the B-cell lineage. During normal immune function, ARID3A helps coordinate:
- B-cell differentiation
- Immunoglobulin gene transcription
- Cell proliferation
- Immune response regulation
- Hematopoietic cell development
A healthy immune system helps regulate ARID3A expression. However, in autoimmune diseases, like SLE, ARID3A activity becomes abnormal.
An excessive amount of ARID3A promotes the survival and activation of autoreactive B cells. As a result, it produces autoantibodies that act against the body’s healthy tissue. So, researchers use ARID3A as a biomarker to understand disease severity and progression.
In addition, B cells get activated during SLE. This occurs because of alterations in transcriptional programs that further promote B-cell survival. At times, researchers calculate the concentration of ARID3A protein in a sample and compare it with ARID3A +ve B-cells and ARID3A -ve B cells. This further helps them understand the disease mechanism.
ARID3A also influences multiple signaling pathways involved in immune regulation. Abnormal levels of ARID3A disturb the balance between immune activation and immune tolerance. As a result, autoreactive cells start to escape normal regulatory mechanisms, leading to SLE.
How Do Anti-ARID3A Antibodies Help in Lupus Research?
Identify ARID3A Expression Patterns
Anti-ARID3A antibodies are used in IHC and IF to determine the location of ARID3A expression in the affected tissues. These proteins can occur in:
- Peripheral blood B cells
- Bone marrow cells
- Lymphoid tissues
- Kidney tissue affected by lupus nephritis
Mapping these expressions helps researchers understand disease pathology and which organs are at higher risk of SLE.
Study Disease Progression
Longitudinal studies usually measure ARID3A levels at different stages of disease. So, researchers use anti-ARID3A antibodies that help them evaluate how ARID3A expression changes during:
- Active disease flare
- Disease remission
- Treatment response
- Chronic inflammation
This further helps researchers understand disease progression.
Investigate Gene Regulation
As a transcription factor, ARID3A directly regulates numerous genes. So, researchers use anti-ARID3A antibodies in ChIP to identify DNA regions where ARID3A binds. This helps them further understand which genes it controls during autoimmune responses.
These studies also reveal molecular pathways that may become further therapeutic targets.
Support Drug Discovery and Therapeutic Development
Once researchers understand how ARID3 proteins contribute to disease progression, they can use this knowledge to develop better therapeutic strategies. They use antibodies in preclinical studies to evaluate whether experimental drugs can:
- Reduce ARID3A expression
- Normalize B-cell function
- Suppress autoreactive immune responses
- Alter downstream signaling pathways
These experiments also help identify the right candidate for clinical trials.
The Bottom Line
Anti-ARID3A antibodies help researchers investigate the molecular mechanisms underlying SLE. They can explore how abnormal B-cell activity contributes to autoimmune disease development and develop new treatments and drugs.
However, choosing high-quality antibodies is crucial. Otherwise, you may have to compromise on your results. So, make sure you choose well-validated antibodies, check application compatibility, host species, species reactivity, etc. This improves reproducibility and confidence in experimental findings. In addition, make sure you choose a trusted supplier.
